Tests a transcatheter valve replacement for severe leaky mitral valve with heart failure symptoms

Trial details

Who runs it

InnovHeart

Trial code

NCT06414265

Record updated

20 May 2026

Original description

The goal of this clinical trial is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach. The main questions it aims to answer are:Read full original descriptionShow less

Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-Septal TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - CASSINI-EU Trial

The goal of this clinical trial is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach. The main questions it aims to answer are:

* is the use of the device feasible? * is it safe (defined as freedom from device-related major adverse events at 30 days)? * does it perform (defined as reduction of MR Grade to ≤ 1+ at 30 days)?

Participants will need to do the following as part of the clinical trial:

* complete 6-Minute Walking Test * complete Quality of Life Questionnaires * undergo blood evaluations * CT scan * 12 lead ECG * Transesophageal Echocardiography * Transthoracic Echocardiogram * the study procedure (valve implantation, right heart catheterization, left arterial pressure, fluoroscopy/ angiogram)

Inclusion: Age 65 years or older; Symptomatic moderate to severe or severe functional mitral regurgitation (≥ Grade 3+); NYHA functional Class ≥ II. If Class IV, patient must be ambulatory; Ability to tolerate oral anticoagulation; Ability to qualify for bailout surgery (which may include open heart surgery); High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team; Willing and able to complete study-related assessments and questionnaires.

Exclusion: Endocarditis in the 3 months prior to procedure date; COPD 2 on home oxygen therapy deemed too high risk for intubation; Myocardial infarction during prior 30 days; Stroke or TIA during prior 90 days; Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed); Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment; Prior surgical mechanical valve AVR; Prior TAVI; CRT or ICD implanted in previous 30 days; CABG or PCI within previous 30 days; Prior or planned heart transplantation (UNOS status 1); Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement; Life expectancy <1 year due to noncardiac conditions; Current admission with acute heart failure exacerbation; Active systemic infection; Severe pulmonary arterial hypertension (PAH), defined as PASP > 60mmHg; Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states); Severe connective tissue disease under chronic immunosuppressive or cortisone therapy; Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure; Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee; Physical evidence of right-sided congestive heart failure:; Patients with ascites; Patients with anasarca (generalized edema / hydropsy); Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy; Procedural Exclusion Criteria; Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy); Documented hypersensitivity to nickel or titanium; Contraindications to TEE imaging; Cardiac Imaging Exclusion Criteria; Chronic renal failure defined as eGFR <30 mL/min/m2 or on renal replacement therapy; Platelets < 90,000; General Exclusion Criteria; Degenerative (i.e. intrinsic valve lesions) mitral regurgitation; Dependency on inotropic agents or mechanical circulatory support; Untreated clinically significant CAD; Modified Rankin Scale ≥4 disability; Refuses blood transfusions; Participating in other investigational studies likely to confound the results or affect the study; Unable or does not sign the study informed consent form; Patients classified as "vulnerable patients" 3 ; Cardiovascular Exclusion Criteria; Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or requiring IABP/mechanical circulatory support; Left ventricular EF ≤ 30% by echocardiogram; Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass; Extensive mitral flail leaflets; Evidence of new or untreated intracardiac thrombus, mass, or vegetation; Severe right ventricular dysfunction; Severe tricuspid regurgitation; Hemodynamically significant inter-atrial shunt (ASD); Severe aortic regurgitation or aortic stenosis; Anatomic ineligibility for SATURN TS Bioprosthetic System or SATURN TS procedure as determined by the Screening Committee.

ClinicalTrials.gov NCT06414265